^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GRWD5769

    i
    Other names: GRWD5769, GRWD-5769, GRWD 5769
    Associations

    News

    Trials
    Company:
    GreyWolf Therapeutics
    Drug class:
    ERAP1 inhibitor
    Associations

    News

    Trials
    7ms
    A clinical trial to determine the safety and tolerability of GRWD5769 in patients with solid malignancies. (ACTRN12623000108617)
    P1, N=60, Active, not recruiting, Grey Wolf Therapeutics Pty Ltd | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    GRWD5769
    11ms
    EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1) (clinicaltrials.gov)
    P1/2, N=288, Recruiting, Grey Wolf Therapeutics
    New P1/2 trial
    |
    Libtayo (cemiplimab-rwlc) • GRWD5769
    1year
    A clinical trial to determine the safety and tolerability of GRWD5769 in combination with anticancer treatments in patients with solid malignancies. (ACTRN12623001077651)
    P1/2, N=168, Recruiting, Grey Wolf Therapeutics Pty Ltd | Phase classification: P1 --> P1/2 | N=36 --> 168
    Phase classification • Enrollment change
    |
    Libtayo (cemiplimab-rwlc) • GRWD5769
    over1year
    A clinical trial to determine the safety and tolerability of GRWD5769 in combination with anticancer treatments in patients with solid malignancies. (ACTRN12623001077651)
    P1, N=36, Recruiting, Grey Wolf Therapeutics Pty Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Libtayo (cemiplimab-rwlc) • GRWD5769
    over1year
    A clinical trial to determine the safety and tolerability of GRWD5769 in patients with solid malignancies. (ACTRN12623000108617)
    P1, N=60, Recruiting, Grey Wolf Therapeutics Pty Ltd | N=36 --> 60
    Enrollment change
    |
    GRWD5769
    over2years
    A clinical trial to determine the safety and tolerability of GRWD5769 in combination with anticancer treatments in patients with solid malignancies. (ACTRN12623001077651)
    P1, N=36, Not yet recruiting, Grey Wolf Therapeutics Pty Ltd
    New P1 trial • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Libtayo (cemiplimab-rwlc) • GRWD5769
    over2years
    A clinical trial to determine the safety and tolerability of GRWD5769 in patients with solid malignancies. (ACTRN12623000108617)
    P1, N=36, Recruiting, Grey Wolf Therapeutics Pty Ltd | Initiation date: Mar 2000 --> Mar 2023
    Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    GRWD5769